SSTR5 antagonist 2
Modify Date: 2025-08-26 12:19:05
SSTR5 antagonist 2 structure
|
Common Name | SSTR5 antagonist 2 | ||
|---|---|---|---|---|
| CAS Number | 1254730-81-8 | Molecular Weight | 546.63 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C32H35FN2O5 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of SSTR5 antagonist 2SSTR5 antagonist 2 (compound 10) is a highly potent, oral active and selective somatostatin (receptor) subtype 5 (SSTR5) antagonist and has potential to treat type 2 diabetes mellitus (T2DM)[1]. |
| Name | 4-{8-[(2,6-diethoxy-4'-fluorobiphenyI-4-yl)methyl]-3-oxo-2,8-diazaspiro[4.5]dec-2-yl}benzoic acid |
|---|
| Description | SSTR5 antagonist 2 (compound 10) is a highly potent, oral active and selective somatostatin (receptor) subtype 5 (SSTR5) antagonist and has potential to treat type 2 diabetes mellitus (T2DM)[1]. |
|---|---|
| Related Catalog | |
| Target |
SSTR5[1]. |
| In Vivo | SSTR5 antagonist 2 (10 mg/kg, orally) increases both total and active circulating incretin hormone GLP1 levels in mice at a dose of 10 mg/kg[1]. SSTR5 antagonist 2 increases pancreatic insulin secretion as well as total and active GLP1 release, and demonstrates synergistic effects in combination with DPP4 inhibitors[1]. Animal Model: Rodent diabetic model without risk of hypoglycemia[1]. Dosage: 10 mg/kg. Administration: Orally. Result: Increased both total and active circulating incretin hormone GLP1 levels. |
| References |
| Molecular Formula | C32H35FN2O5 |
|---|---|
| Molecular Weight | 546.63 |
| Exact Mass | 546.25300 |
| PSA | 79.31000 |
| LogP | 6.01030 |